Table 1 Patient characteristics
|  | Transperineal biopsy (N = 92) | Transrectal biopsy (N = 85) | p |
|---|---|---|---|
Total number of targets | 104 | 92 | Â |
Age | 66 (61–72) | 67 (62–73) | 0.61 |
DRE, n (%) | Â | Â | 0.312 |
 Negative | 65 (70.6%) | 62 (72.9%) |  |
 Positive | 27 (29.3%) | 23 (27.0%) |  |
Previous biopsy, n (%) | Â | Â | 0.844 |
 Biopsy naïve | 64 (69.5%) | 57 (67.0%) |  |
 Repeat biopsy | 28 (30.4%) | 28 (32.9%) |  |
PSA, ng/mL | 7.5 (5.30–13.28) | 8.04 (5.76–12.12) | 0.608 |
Prostate volume, ml | 42.34 (29.93–59.08) | 43.4 (30.9–54.9) | 0.582 |
PSAD | 0.18 (0.11–0.32) | 0.18 (0.12–0.27) | 0.729 |
PI-RAS score, n (%) | Â | Â | 0.277 |
 3 | 19 (18.2%) | 13 (14.1%) |  |
 4 | 48 (46.1%) | 53 (57.6%) |  |
 5 | 37 (35.5%) | 26 (28.2%) |  |
Total core number, n | 26 (23–28) | 20 (16–22) | < 0.001 |
 Targeted biopsy | 6 (4–7) | 4 (3–4) | < 0.001 |
 Systematic biopsy | 19 (17–22) | 16 (12–18) | < 0.001 |
Target lesion size, mm | 12 (9–19.25) | 10.5 (6.75–16) | 0.305 |
Target lesion location, n (%) | Â | Â | Â |
 Anterior | 41 (39.4%) | 31 (33.6%) | 0.406 |
 posterior | 63 (60.5%) | 61 (66.3%) |  |